Gilead’s Trodelvy Wins In TROPiCS-02, But Commercial Headwinds Remain

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Analysts said that while the Phase III survival data could lead to Trodelvy’s FDA approval, it still could face competitive headwinds from AstraZeneca/Daiichi Sankyo’s Enhertu.

Gilead announced an OS benefit in the Phase III TROPiCS-02 trial, but Trodelvy faces commercial headwinds • Source: Shutterstock

Gilead Sciences, Inc.’s latest results from the closely watched TROPiCS-02 trial of Trodelvy (sacituzumab govitecan-hziy) in previously treated metastatic hormone receptor (HR)-positive/HER2-negative breast cancer met the key secondary endpoint of overall survival (OS), but without detailed results it remains unclear whether that will help the drug’s competitive position on the market relative to other therapies that have also shown a survival advantage.

Without disclosing the data, the company said 15 August that the Phase III trial, in patients previously treated with endocrine...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.